Chronic Hepatitis B virus infection
Clinical research in chronic hepatitis B centers on investigational antiviral approaches aimed at controlling persistent infection and reducing viral activity. The sponsor’s work in this area includes studies of novel regimens designed to address long-standing HBV infection and related treatment outcomes.
- Antiviral treatment for persistent HBV infection
- Viral suppression and serologic response
- Safety and tolerability of combination regimens
These trials reflect a focus on chronic viral liver disease and the development of therapies with potential to improve disease control in hepatology.
Chronic Hepatitis D virus infection
The largest share of the sponsor’s research activity is directed toward chronic hepatitis D, a severe viral liver infection with limited treatment options. Studies examine antiviral combinations intended to improve HDV control in people with ongoing infection, including those with prior treatment exposure or incomplete viral suppression.
- HDV antiviral therapy
- Persistent infection after prior treatment
- Virologic response and treatment-related safety
Research in this area also includes evaluation of therapeutic strategies for patients who interrupt treatment, highlighting interest in durable viral control in hepatic infectious disease.
Prostate cancer
In hormone-refractory prostate cancer, the sponsor is investigating oncology therapies for advanced disease. The research program includes early clinical evaluation of agents intended for patients whose cancer no longer responds to hormonal treatment, with attention to disease control and treatment effects in urologic oncology.
- Advanced prostate cancer
- Hormone-refractory disease
- Oncology safety and preliminary activity
This area links the sponsor’s development work to difficult-to-treat solid tumors requiring new therapeutic options.
HER2-expressing cancers
Another oncology focus is HER2-expressing cancers that are locally advanced or metastatic. The sponsor’s studies in this setting examine therapies for patients with more widespread disease, including combinations relevant to immuno-oncology and targeted cancer treatment.
- Metastatic solid tumors
- HER2-expressing malignancies
- Combination treatment in advanced cancer
These trials place emphasis on therapeutic options for aggressive cancers with significant unmet clinical need.
